AstraZeneca’s lung cancer drug reached the Phase III, an encouraging sign for patients.
The AURA3 trial had better free survival rates higher than chemotherapy based on platinum.
The study involved 400 patients with locally advanced or metastatic cell lung cancer. The patients’ disease progressed after the EGFR TKI therapy.
While the survival rate was high, the objective response rate, the duration of response and the disease control rate were also improved in comparison with what happened after chemotherapy.
A future medical meeting will discuss the numbers and the exact rates of efficiency. The scheduled meeting will also involve sharing information on the general survival rate.
Other clinical trials have demonstrated that the drug is indeed efficient. The median survival rate was then set to be 8.6 months during the intermediate part of the study.
The FDA already approved the AstraZeneca’s tablet, which is dedicated to EGFR mutation patients and for those that do not respond well to other medication.
As the drug had been relatively quickly approved by the FDA, it seems that it will have a green light in the next evaluation meeting too. FDA shows confidence in the efficiency of the medication.
The drug is one of the most valuable assets of the company. Up to 2023, the sales are supposed to reach $45 billion. Tagrisso, the already approved pill, is said to be able to bring AstraZeneca $3 billion.
Tagrisso had already proved its efficiency in lung cancer patients. The results of the clinical trial showed its effectiveness in solving the most common factor of resistance to traditional treatment.
The company plans to develop new complementary drugs and methods of treatment for the cancer lung that would work well and provide even better results.
AstraZeneca introduced Iressa, another first-line treatment for cancer patients with specific gene mutations. Last year, the drug brought $543 million in sales.
Lung cancer killed 158,040 people last year in the US. There had been another 221,200 new diagnoses in 2015.
At this moment, Roche and Pfizer both have lung cancer drugs on the market, but for different clinical settings and different gene mutations.
Tumors always develop resistance to treatment, so that each pharmaceutical company tries to find ways to help the efficiency of the currently available cures or to develop new therapies which would have better results.
Merck and Bristol-Myers are working on a checkpoint inhibitor that had received approval for the first-line setting.
Image Source: Vimeo
Latest posts by Christina Langfold (see all)
- Scientists Discover the Second Fastest Spinning Pulsar In The Universe - Mar 18, 2019
- Coral Reef Damage Scares Florida Keys Researchers and Businesses - Mar 18, 2019
- Nike to Slash Global Workforce by 1,400 - Mar 18, 2019